AB toxins: A paradigm switch from deadly to desirable

Toxins

Volumn 2, Issue 7, 2010, Pages 1612-1645

  Odumosu, Oludare ^a   Nicholas, Dequina ^a   Yano, Hiroshi ^b   Langridge, William ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF REDLANDS   (United States)

Author keywords

AB toxins; Adjuvants; Enterotoxins; Immunomodulation; Plants; Ricin; Vaccines

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL TOXIN; CHOLERA TOXIN; CHOLERA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI VACCINE; INFLUENZA VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PLANT TOXIN; RECOMBINANT VACCINE; RICIN; SHIGA TOXIN; VEROTOXIN;

ALLERGIC ENCEPHALOMYELITIS; ALPHA CHAIN; ANTHRAX; AUTOIMMUNITY; BETA CHAIN; CHOLERA; CHONDRITIS; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; ESCHERICHIA COLI INFECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOLECULAR PATHOLOGY; NEOPLASM; NONHUMAN; PERTUSSIS; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXIN ANALYSIS; TOXIN STRUCTURE; UVEITIS; VACCINE PRODUCTION;

ANIMALS; BACTERIAL TOXINS; HUMANS; MOLECULAR STRUCTURE; PROTEIN SUBUNITS; RICIN;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 79952078677     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2071612     Document Type: Review

References (201)

1. Finkelstein, R.A.; LoSpalluto,J.J. Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid. J. Exp. Med. 1969, 130, 185-202.
2. Lonnroth, I.; Holmgren, J. Subunit structure of cholera toxin. J. Gen. Microbiol. 1973, 76, 417-427.
3. Sattler, J.; Wiegandt, H. Studies of the subunit structure of choleragen. Eur. J. Biochem. 1975, 57, 309-316.
4. Sixma, T.K.; Kalk, K.H.; van Zanten, B.A.; Dauter, Z.; Kingma, J.; Witholt, B.; Hol, W.G. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol. 1993, 230, 890-918.
5. Merritt, E.A.; Sarfaty, S.; Chang, T.T.; Palmer, L.M.; Jobling, M.G.; Holmes, R.K.; Hol, W.G. Surprising leads for a cholera toxin receptor-binding antagonist: crystallographic studies of CTB mutants. Structure 1995, 3, 561-570.
6. Holmgren, J.; Lonnroth, I.; Svennerholm, L. Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids. Infect. Immun. 1973, 8, 208-214.
7. Holmgren, J.; Lonnroth, I.; Mansson, J.; Svennerholm, L. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc. Natl. Acad. Sci. USA 1975, 72, 2520-2524.
8. van Heyningen, W.E.; King, C.A. The role of gangliosides in the action of cholera toxin. Adv. Exp. Med. Biol. 1976, 71, 205-214.
9. van Heyningen, S. The subunits of cholera toxin: structure, stoichiometry, and function. J. Infect. Dis. 1976, 133 Suppl, 5-13.
10. Holmgren, J.; Lindholm, L.; Lonnroth, I. Interaction of cholera toxin and toxin derivatives with lymphocytes. I. Binding properties and interference with lectin-induced cellular stimulation. J. Exp. Med. 1974, 139, 801-819.
11. Sanchez, J.; Holmgren, J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci. 2008, 65, 1347-1360.
12. Camberg, J.L.; Johnson, T.L.; Patrick, M.; Abendroth, J.; Hol, W.G.; Sandkvist, M. Synergistic stimulation of EpsE ATP hydrolysis by EpsL and acidic phospholipids. EMBO J. 2007, 26, 19-27.
13. Camberg, J.L.; Sandkvist, M. Molecular analysis of the Vibrio cholerae type II secretion ATPase EpsE. J. Bacteriol. 2005, 187, 249-256.
14. Davis, B.M.; Lawson, E.H.; Sandkvist, M.; Ali, A.; Sozhamannan, S.; Waldor, M.K. Convergence of the secretory pathways for cholera toxin and the filamentous phage, CTXphi. Science 2000, 288, 333-335.
15. Hirst, T.R.; Sanchez, J.; Kaper, J.B.; Hardy, S.J.; Holmgren, J. Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. Proc. Natl. Acad. Sci. USA 1984, 81, 7752-7756.
16. Hardy, S.J.; Holmgren, J.; Johansson, S.; Sanchez, J.; Hirst, T.R. Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. Proc. Natl. Acad. Sci. USA 1988, 85, 7109-7113.
17. Merritt, E.A.; Sarfaty, S.; van den Akker, F.; L'Hoir, C.; Martial, J.A.; Hol, W.G. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994, 3, 166-175.
18. Jobling, M.G.; Holmes, R.K. Mutational analysis of ganglioside GM(1)-binding ability, pentamer formation, and epitopes of cholera toxin B (CTB) subunits and CTB/heat-labile enterotoxin B subunit chimeras. Infect. Immun. 2002, 70, 1260-1271.
19. Merritt, E.A.; Hol, W.G. AB5 toxins. Curr. Opin. Struct. Biol. 1995, 5, 165-171.
20. Chinnapen, D.J.; Chinnapen, H.; Saslowsky, D.; Lencer, W.I. Rafting with cholera toxin: Endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol. Lett. 2007, 266, 129-137.
21. Massol, R.H.; Larsen, J.E.; Fujinaga, Y.; Lencer, W.I.; Kirchhausen, T. Cholera toxin toxicity does not require functional Arf6- and dynamin-dependent Endocytic pathways. Mol. Biol. Cell. 2004, 15, 3631-3641.
22. Sandvig, K.; van Deurs, B. Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin. FEBS Lett. 2002, 529, 49-53.
23. Spooner, R.A.; Smith, D.C.; Easton, A.J.; Roberts, L.M.; Lord, J.M. Retrograde transport pathways utilised by viruses and protein toxins. Virol. J. 2006, 3, 26.
24. O'Neal, C.J.; Jobling, M.G.; Holmes, R.K.; Hol, W.G. Structural basis for the activation of cholera toxin by human ARF6-GTP. Science 2005, 309, 1093-1096.
25. Guidry, J.J.; Cardenas, L.; Cheng, E.; Clements, J.D. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect. Immun. 1997, 65, 4943-4950.
26. Porgador, A.; Staats, H.F.; Itoh, Y.; Kelsall, B.L. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect. Immun. 1998, 66, 5876-5881.
27. Sun, J.B.; Holmgren, J.; Czerkinsky, C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 1994, 91, 10795-10799.
28. Czerkinsky, C.; Sun, J.B.; Lebens, M.; Li, B.L.; Rask, C.; Lindblad, M.; Holmgren, J. Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Ann. N. Y. Acad. Sci. 1996, 778, 185-193.
29. Sun, J.B.; Xiao, B.G.; Lindblad, M.; Li, B.L.; Link, H.; Czerkinsky, C.; Holmgren, J. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-beta- secreting cells and suppressing chemokine expression. Int. Immunol. 2000, 12, 1449-1457.
30. Eriksson, K.; Holmgren, J. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 2002, 14, 666-672.
31. Lucas, M.E.; Deen, J.L.; von Seidlein, L.; Wang, X.Y.; Ampuero, J.; Puri, M.; Ali, M.; Ansaruzzaman, M.; Amos, J.; Macuamule, A.; Cavailler, P.; Guerin, P.J.; Mahoudeau, C.; Kahozi-Sangwa, P.; Chaignat, C.L.; Barreto, A.; Songane, F.F.; Clemens, J.D. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med. 2005, 352, 757-767.
32. George-Chandy, A.; Eriksson, K.; Lebens, M.; Nordstrom, I.; Schon, E.; Holmgren, J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect. Immun. 2001, 69, 5716-5725.
33. D'Ambrosio, A.; Colucci, M.; Pugliese, O.; Quintieri, F.; Boirivant, M. Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J. Leukoc. Biol. 2008, 84, 661-668.
34. Kim, N.; Cheng, K.C.; Kwon, S.S.; Mora, R.; Barbieri, M.; Yoo, T.J. Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease. Ann. Otol. Rhinol. Laryngol. 2001, 110, 646-654.
35. Phipps, P.A.; Stanford, M.R.; Sun, J.B.; Xiao, B.G.; Holmgren, J.; Shinnick, T.; Hasan, A.; Mizushima, Y.; Lehner, T. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur. J. Immunol. 2003, 33, 224-232.
36. Bergerot, I.; Ploix, C.; Petersen, J.; Moulin, V.; Rask, C.; Fabien, N.; Lindblad, M.; Mayer, A.; Czerkinsky, C.; Holmgren, J.; Thivolet, C. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. USA 1997, 94, 4610-4614.
37. Arakawa, T.; Yu, J.; Chong, D.K.; Hough, J.; Engen, P.C.;Langridge, W.H. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat. Biotechnol. 1998, 16, 934-938.
38. Aspord, C.; Thivolet, C. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 2002, 130, 204-211.
39. Roncarolo, M.G.; Levings, M.K.; Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 2001, 193, F5-F9.
40. Arakawa, T.; Chong, D.K.; Langridge, W.H. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 1998, 16, 292-297.
41. Marinaro, M.; Staats, H.F.; Hiroi, T.; Jackson, R.J.; Coste, M.; Boyaka, P.N.; Okahashi, N.; Yamamoto, M.; Kiyono, H.; Bluethmann, H.; Fujihashi, K.; McGhee, J.R. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 1995, 155, 4621-4629.
42. Lavelle, E.C.; Jarnicki, A.; McNeela, E.; Armstrong, M.E.; Higgins, S.C.; Leavy, O.; Mills, K.H. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 2004, 75, 756-763.
43. Lavelle, E.C.; McNeela, E.; Armstrong, M.E.; Leavy, O.; Higgins, S.C.; Mills, K.H. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 2003, 171, 2384-2392.
44. Isomura, I.; Yasuda, Y.; Tsujimura, K.; Takahashi, T.; Tochikubo, K.; Morita, A. Recombinant cholera toxin B subunit activates dendritic cells and enhances antitumor immunity. Microbiol. Immunol. 2005, 49, 79-87.
45. Ploix, C.; Bergerot, I.; Durand, A.; Czerkinsky, C.; Holmgren, J.; Thivolet, C. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes 1999, 48, 2150-2156.
46. Sun, J.B.; Czerkinsky, C.; Holmgren, J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol. 2010, 71,1-11.
47. Denes, B.; Fodor, I.; Odumosu, O.; Langridge, W. Multi-factorial Vaccine Suppression of Diabetes Autoimmunity. 2010, Unpublished work.
48. Sixma, T.K.; Pronk, S.E.; Kalk, K.H.; Wartna, E.S.; van Zanten, B.A.; Witholt, B.; Hol, W.G. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 1991, 351, 371-377.
49. van den Akker, F.; Sarfaty, S.; Twiddy, E.; Connell, T.; Holmes, R.; Hol, W. Crystal structure of a new heat-labile enterotoxin, LT-IIb. Structure 1996, 4, 665-678.
50. Alone, P.V.; Malik, G.; Krishnan, A.; Garg, L.C. Deletion mutations in N-terminal alpha1 helix render heat labile enterotoxin B subunit susceptible to degradation. Proc. Natl. Acad. Sci. USA 2007, 104, 16056-16061.
51. Alone, P.V.; Garg, L.C. Secretory and GM1 receptor binding role of N-terminal region of LTB in Vibrio cholerae. Biochem. Biophys. Res. Commun. 2008, 376, 770-774.
52. Chung, W.Y.; Carter, R.; Hardy, T.; Sack, M.; Hirst, T.R.; James, R.F. Inhibition of Escherichia coli heat-labile enterotoxin B subunit pentamer (EtxB5) assembly in vitro using monoclonal antibodies. J. Biol. Chem. 2006, 281, 39465-39470.
53. Schengrund, C.L.; Ringler, N.J. Binding of Vibrio cholera toxin and the heat-labile enterotoxin of Escherichia coli to GM1, derivatives of GM1, and nonlipid oligosaccharide polyvalent ligands. J. Biol. Chem. 1989, 264, 13233-13237.
54. Sixma, T.K.; Pronk, S.E.; Kalk, K.H.; van Zanten, B.A.; Berghuis, A.M.; Hol, W.G. Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature 1992, 355, 561-564.
55. Karlsson, K.A.; Teneberg, S.; Angstrom, J.; Kjellberg, A.; Hirst, T.R.; Berstrom, J.; Miller-Podraza, H. Unexpected carbohydrate cross-binding by Escherichia coli heat-labile enterotoxin. Recognition of human and rabbit target cell glycoconjugates in comparison with cholera toxin. Bioorg. Med. Chem. 1996, 4, 1919-1928.
56. Critchley, D.R.; Magnani, J.L.; Fishman, P.H. Interaction of cholera toxin with rat intestinal brush border membranes. Relative roles of gangliosides and galactoproteins as toxin receptors. J. Biol. Chem. 1981, 256, 8724-8731.
57. Orlandi, P.A.; Critchley, D.R.; Fishman, P.H. The heat-labile enterotoxin of Escherichia coli binds to polylactosaminoglycan-containing receptors in CaCo-2 human intestinal epithelial cells. Biochemistry 1994, 33, 12886-12895.
58. Fukuta, S.; Magnani, J.L.; Twiddy, E.M.; Holmes, R.K.; Ginsburg, V. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 1988, 56, 1748-1753.
59. Fujinaga, Y.; Wolf, A.A.; Rodighiero, C.; Wheeler, H.; Tsai, B.; Allen, L.; Jobling, M.G.; Rapoport, T.; Holmes, R.K.; Lencer, W.I. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to Endoplasmic reticulm. Mol. Biol. Cell. 2003, 14, 4783-4793.
60. Spangler, B.D. Structure and Function of Cholera-Toxin and the Related Escherichia-Coli Heat-Labile Enterotoxin. Microbiol. Mol. Biol. Rev. 1992, 56, 622-647.
61. Couch, R.B. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 2004, 350, 860-861.
62. Lopes, L.M.; Maroof, A.; Dougan, G.; Chain, B.M. Inhibition of T-cell response by Escherichia coli heat-labile enterotoxin-treated epithelial cells. Infect. Immun. 2000, 68, 6891-6895.
63. Negri, D.R.; Pinto, D.; Vendetti, S.; Patrizio, M.; Sanchez, M.; Riccomi, A.; Ruggiero, P.; Del Giudice, G.; De Magistris, M.T. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Infect. Immun. 2009, 77, 1924-1935.
64. Hajishengallis, G.; Nawar, H.; Tapping, R.I.; Russell, M.W.; Connell, T.D. The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells. Infect. Immun. 2004, 72, 6351-6358.
65. Domingos, M.O.; Andrade, R.G.; Barbaro, K.C.; Borges, M.M.; Lewis, D.J.; New, R.R. Influence of the A and B subunits of cholera toxin (CT) and Escherichia coli toxin (LT) on TNF-alpha release from macrophages. Toxicon 2009, 53, 570-577.
66. Lee, C.H.; Nawar, H.F.; Mandell, L.; Liang, S.; Hajishengallis, G.; Connell, T.D. Enhanced antigen uptake by dendritic cells induced by the B pentamer of the type II heat-labile enterotoxin LT-IIa requires engagement of TLR2. Vaccine 2010, 28, 3696-3705.
67. Liang, S.; Hosur, K.B.; Nawar, H.F.; Russell, M.W.; Connell, T.D.; Hajishengallis, G. In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli. Vaccine 2009, 27, 4302-4308.
68. Anosova, N.G.; Chabot, S.; Shreedhar, V.; Borawski, J.A.; Dickinson, B.L.; Neutra, M.R. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal. Immunol. 2008, 1, 59-67.
69. Glenn, G.M.; Thomas, D.N.; Poffenberger, K.L.; Flyer, D.C.; Ellingsworth, L.R.; Andersen, B.H.; Frech, S.A. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 2009, 27 (Suppl. 6), G60-G66.
70. Alfano, M.; Rizzi, C.; Corti, D.; Adduce, L.; Poli, G. Bacterial toxins: potential weapons against HIV infection. Curr. Pharm. Des. 2005, 11, 2909-2926.
71. Zhou, W.Y.; Shi, Y.; Wu, C.; Zhang, W.J.; Mao, X.H.; Guo, G.; Li, H.X.; Zou, Q.M. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 2009, 27, 5013-5019.
72. Facciabene, A.; Aurisicchio, L.; Elia, L.; Palombo, F.; Mennuni, C.; Ciliberto, G.; La Monica, N. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007, 26, 47-58.
73. Lemere, C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 2009, 175, 83-93.
74. Ryan, E.J.; McNeela, E.; Pizza, M.; Rappuoli, R.; O'Neill, L.; Mills, K.H. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and antiinflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 2000, 165, 5750-5759.
75. Raveney, B.J.; Richards, C.; Aknin, M.L.; Copland, D.A.; Burton, B.R.; Kerr, E.; Nicholson, L.B.; Williams, N.A.; Dick, A.D. The B subunit of Escherichia coli heat-labile enterotoxin inhibits Th1 but not Th17 cell responses in established experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2008, 49, 4008-4017.
76. Scerbo, M.J.; Rupil, L.L.; Bibolini, M.J.; Roth, G.A.; Monferran, C.G. Protective effect of a synapsin peptide genetically fused to the B subunit of Escherichia coli heat-labile enterotoxin in rat autoimmune encephalomyelitis. J. Neurosci. Res. 2009, 87, 2273-2281.
77. Carter, J.E., III; Yu, J.; Choi, N.W.; Hough, J.; Henderson, D.; He, D.; Langridge, W.H. Bacterial and plant enterotoxin B subunit-autoantigen fusion proteins suppress diabetes insulitis. Mol. Biotechnol. 2006, 32, 1-15.
78. Ravin, N.V.; Kuprianov, V.V.; Zamchuk, L.A.; Kochetov, A.V.; Dorokhov, Y.L.; Atabekov, J.G.; Skryabin, K.G. Highly efficient expression of Escherichia coli heat-labile enterotoxin B subunit in plants using potato virus X-based vector. Biochemistry (Mosc) 2008, 73, 1108-1113.
79. Chikwamba, R.; Cunnick, J.; Hathaway, D.; McMurray, J.; Mason, H.; Wang, K. A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res. 2002, 11, 479-493.
80. Kim, T.G.; Kim, M.Y.; Kim, B.G.; Kang, T.J.; Kim, Y.S.; Jang, Y.S.; Arntzen, C.J.; Yang, M.S. Synthesis and assembly of Escherichia coli heat-labile enterotoxin B subunit in transgenic lettuce (Lactuca sativa). Protein Expr. Purif. 2007, 51, 22-27.
81. Rosales-MEndoza, S.; Soria-Guerra, R.E.; Lopez-Revilla, R.; Moreno-Fierros, L.; Alpuche-Solis, A.G. Ingestion of transgenic carrots expressing the Escherichia coli heat-labile enterotoxin B subunit protects mice against cholera toxin challenge. Plant Cell Rep. 2008, 27, 79-84.
82. Zhang, X.; Yuan, Z.; Duan, Q.; Zhu, H.; Yu, H.; Wang, Q. Mucosal immunity in mice induced by orally administered transgenic rice. Vaccine 2009, 27, 1596-1600.
83. Trofa, A.F.; Ueno-Olsen, H.; Oiwa, R.; Yoshikawa, M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin. Infect. Dis. 1999, 29, 1303-1306.
84. Strelkauskas, A.J., Stelkauskas, J.E., Moszyk-Strelkauskas, D. Microbiology: A Clinical Approach; Garland Science: New York, NY, USA, 2010.
85. Johannes, L.; Romer, W. Shiga toxins-from cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8, 105-116.
86. Sandvig, K. Shiga toxins. Toxicon 2001, 39, 1629-1635.
87. Wilson, C.B.; Rowell, E.; Sekimata, M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 2009, 9, 91-105.
88. Melton-Celsa, A.R.; Darnell, S.C.; O'Brien, A.D. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect. Immun. 1996, 64, 1569-1576.
89. Fraser, M.E.; Chernaia, M.M.; Kozlov, Y.V.; James, M.N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat. Struct. Biol. 1994, 1, 59-64.
90. Sandvig, K.; van Deurs, B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J. 2000, 19, 5943-5950.
91. Sandvig, K.; Grimmer, S.; Iversen, T.G.; Rodal, K.; Torgersen, M.L.; Nicoziani, P.; van Deurs, B. Ricin transport into cells: studies of Endocytosis and intracellular transport. Int. J. Med. Microbiol. 2000, 290, 415-420.
92. Haicheur, N.; Benchetrit, F.; Amessou, M.; Leclerc, C.; Falguieres, T.; Fayolle, C.; Bismuth, E.; Fridman, W.H.; Johannes, L.; Tartour, E. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int. Immunol. 2003, 15, 1161-1171.
93. Ohmura, M.; Yamamoto, M.; Tomiyama-Miyaji, C.; Yuki, Y.; Takeda, Y.; Kiyono, H. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation. Infect. Immun.2005, 73, 4088-4097.
94. Adotevi, O.; Vingert, B.; Freyburger, L.; Shrikant, P.; Lone, Y.C.; Quintin-Colonna, F.; Haicheur, N.; Amessou, M.; Herbelin, A.; Langlade-Demoyen, P.; Fridman, W.H.; Lemonnier, F.; Johannes, L.; Tartour, E. B subunit of Shiga toxin-based vaccines synergize with alpha- galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J. Immunol. 2007, 179, 3371-3379.
95. Oloomi, M.; Bouzari, S.; Emami, S. A recombinant hybrid peptide composed of AAF adhesin of enteroaggregative Escherichia coli and Shiga toxin B subunit elicits protective immune response in mice. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28, 1311-1316.
96. al-Jaufy, A.Y.; Haddad, J.E.; King, S.R.; McPhee, R.A.; Jackson, M.P. Cytotoxicity of a shiga toxin A subunit-CD4 fusion protein to human immunodeficiency virus-infected cells. Infect. Immun. 1994, 62, 956-960.
97. Stein, P.E.; Boodhoo, A.; Armstrong, G.D.; Cockle, S.A.; Klein, M.H.; Read, R.J. The crystal structure of pertussis toxin. Structure 1994, 2, 45-57.
98. Plaut, R.D.; Carbonetti, N.H. Retrograde transport of pertussis toxin in the mammalian cell. Cell Microbiol. 2008, 10, 1130-1139.
99. Oakley, C.L. Jules Jean Baptiste Vincent Bordet. 1870-1961. Biogr. Mem. Fellows R. Soc. 1962, 19-25.
100. Center for Diseases Control and Prevention (CDC). Pertussis (Whooping Cough) Vaccination. Available online: http://www.cdc.gov/vaccines/vpd-vac/pertussis/default.htm (Accessed on 21 June 2010).
101. Bagley, K.C.; Abdelwahab, S.F.; Tuskan, R.G.; Fouts, T.R.; Lewis, G.K. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J. Leukoc. Biol. 2002, 72, 962-969.
102. Worthington, Z.E.; Carbonetti, N.H. Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation. Infect. Immun. 2007, 75, 2946-2953.
103. Hausman, S.Z.; Burns, D.L. Binding of pertussis toxin to lipid vesicles containing glycolipids. Infect. Immun. 1993, 61, 335-337.
104. el Baya, A.; Linnemann, R.; von Olleschik-Elbheim, L.; Robenek, H.; Schmidt, M.A. Endocytosis and retrograde transport of pertussis toxin to the Golgi complex as a prerequisite for cellular intoxication. Eur. J. Cell Biol. 1997, 73, 40-48.
105. Xu, Y.; Barbieri, J.T. Pertussis toxin-mediated ADP-ribosylation of target proteins in Chinese hamster ovary cells involves a vesicle trafficking mechanism. Infect. Immun. 1995, 63, 825-832.
106. Wang, Z.Y.; Yang, D.; Chen, Q.; Leifer, C.A.; Segal, D.M.; Su, S.B.; Caspi, R.R.; Howard, Z.O.; Oppenheim, J.J. Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially initiate Toll-like receptor 4-dependent signal transduction pathways. Exp. Hematol. 2006, 34, 1115-1124.
107. Fujimoto, C.; Yu, C.R.; Shi, G.; Vistica, B.P.; Wawrousek, E.F.; Klinman, D.M.; Chan, C.C.; Egwuagu, C.E.; Gery, I. Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J. Immunol. 2006, 177, 6896-6903.
108. Hou, W.; Wu, Y.; Sun, S.; Shi, M.; Sun, Y.; Yang, C.; Pei, G.; Gu, Y.; Zhong, C.; Sun, B. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J. Immunol. 2003, 170, 1728-1736.
109. + T regulatory cells. Eur. J. Immunol. 2006, 36, 671-680.
110. Alfano, M.; Schmidtmayerova, H.; Amella, C.A.; Pushkarsky, T.; Bukrinsky, M. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J. Exp. Med. 1999, 190, 597-605.
111. Alfano, M.; Pushkarsky, T.; Poli, G.; Bukrinsky, M. The B-oligomer of pertussis toxin inhibits human immunodeficiency virus type 1 replication at multiple stages. J. Virol. 2000, 74, 8767-8770.
112. Rizzi, C.; Crippa, M.P.; Jeeninga, R.E.; Berkhout, B.; Blasi, F.; Poli, G.; Alfano, M. Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1. J. Immunol. 2006, 176, 999-1006.
113. van der Goot, G.; Young, J.A. Receptors of anthrax toxin and cell entry. Mol. Aspects Med. 2009, 30, 406-412.
114. Remacle, A.G.; Gawlik, K.; Golubkov, V.S.; Cadwell, G.W.; Liddington, R.C.; Cieplak, P.; Millis, S.Z.; Desjardins, R.; Routhier, S.; Yuan, X.W.; Neugebauer, W.A.; Day, R.; Strongin, A.Y. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int. J. Biochem. Cell Biol. 2010, 42, 987-995.
115. Lacy, D.B.; Wigelsworth, D.J.; Melnyk, R.A.; Harrison, S.C.; Collier, R.J. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. USA 2004, 101, 13147-13151.
116. Abrami, L.; Liu, S.; Cosson, P.; Leppla, S.H.; van der Goot, F.G. Anthrax toxin triggers Endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 2003, 160, 321-328.
117. Mogridge, J.; Cunningham, K.; Collier, R.J. Stoichiometry of anthrax toxin complexes. Biochemistry 2002, 41, 1079-1082.
118. Abrami, L.; Kunz, B.; van der Goot, F.G. Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake. Proc. Natl. Acad. Sci. USA 2010, 107, 1420-1424.
119. Tama, F.; Ren, G.; Brooks, C.L., III; Mitra, A.K. Model of the toxic complex of anthrax: responsive conformational changes in both the lethal factor and the protective antigen heptamer. Protein Sci. 2006, 15, 2190-2200.
120. Abrami, L.; Bischofberger, M.; Kunz, B.; Groux, R.; van der Goot, F.G. Endocytosis of the anthrax toxin is mediated by clathrin, actin and unconventional adaptors. PLoS Pathog. 2010, 6, e1000792.
121. Gao, M.; Schulten, K. Onset of anthrax toxin pore formation. Biophys. J. 2006, 90, 3267-3279.
122. Basilio, D.; Juris, S.J.; Collier, R.J.; Finkelstein, A. Evidence for a proton-protein symport mechanism in the anthrax toxin channel. J. Gen. Physiol. 2009, 133, 307-314.
123. Wesche, J.; Elliott, J.L.; Falnes, P.O.; Olsnes, S.; Collier, R.J. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 1998, 37, 15737-15746.
124. Thoren, K.L.; Worden, E.J.; Yassif, J.M.; Krantz, B.A. Lethal factor unfolding is the most force-dependent step of anthrax toxin translocation. Proc. Natl. Acad. Sci. USA 2009, 106, 21555-21560.
125. Janowiak, B.E.; Fischer, A.; Collier, R.J. Effects of introducing a single charged residue into the phenylalanine clamp of multimeric anthrax protective antigen. J. Biol. Chem. 2010, 285, 8130-8137.
126. Zhang, S.; Finkelstein, A.; Collier, R.J. Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel. Proc. Natl. Acad. Sci. USA 2004, 101, 16756-16761.
127. Halverson, K.M.; Panchal, R.G.; Nguyen T.L.; Gussio, R.; Little, S.F.; Misakian, M.; Bavari, S.; Kasianowicz, J.J. Anthrax biosensor, protective antigen ion channel asymmetric blockade. J. Biol. Chem. 2005, 280, 34056-34062.
128. Duesbery, N.S.; Webb, C.P.; Leppla, S.H.; Gordon, V.M.; Klimpel, K.R.; Copeland, T.D.; Ahn, N.G.; Oskarsson, M.K.; Fukasawa, K.; Paull, K.D.; Vande Woude, G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737.
129. Vitale, G.; Pellizzari, R.; Recchi, C.; Napolitani, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 1998, 248, 706-711.
130. Pannifer, A.D.; Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J.; Lacy, D.B.; Collier, R.J.; Park, S.; Leppla, S.H.; Hanna, P.; Liddington, R.C. Crystal structure of the anthrax lethal factor. Nature 2001, 414, 229-233.
131. Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000, 352 (Pt 3), 739-745.
132. Shen, Y.; Zhukovskaya, N.L.; Guo, Q.; Florian, J.; Tang, W.J. Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J. 2005, 24, 929-941.
133. Leppla, S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 1982, 79, 3162-3166.
134. Rossi Paccani, S.; Tonello, F.; Patrussi, L.; Capitani, N.; Simonato, M.; Montecucco, C.; Baldari, C.T. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell Microbiol. 2007, 9, 924-929.
135. Szarowicz, S.E.; During, R.L.; Li, W.; Quinn, C.P.; Tang, W.J.; Southwick, F.S. Bacillus anthracis edema toxin impairs neutrophil actin-based motility. Infect. Immun. 2009, 77, 2455-2464.
136. Hong, J.; Doebele, R.C.; Lingen, M.W.; Quilliam, L.A.; Tang, W.J.; Rosner, M.R. Anthrax edema toxin inhibits Endothelial cell chemotaxis via Epac and Rap1. J. Biol. Chem. 2007, 282, 19781-19787.
137. Kim, J.S.; Bokoch, G.M. Anthrax edema toxin inhibits Nox1-mediated formation of reactive oxygen species by colon epithelial cells. J. Innate Immun. 2009, 1, 145-152.
138. Ono, K.; Han, J. The p38 signal transduction pathway: activation and function. Cell. Signal. 2000, 12, 1-13.
139. Park, J.M.; Greten, F.R.; Li, Z.W.; Karin, M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002, 297, 2048-2051.
140. Popov, S.G.; Villasmil, R.; Bernardi, J.; Grene, E.; Cardwell, J.; Wu, A.; Alibek, D.; Bailey, C.; Alibek, K. Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. 2002, 293, 349-355.
141. Wu, W.; Mehta, H.; Chakrabarty, K.; Booth, J.L.; Duggan, E.S.; Patel, K.B.; Ballard, J.D.; Coggeshall, K.M.; Metcalf, J.P. Resistance of human alveolar macrophages to Bacillus anthracis lethal toxin. J. Immunol. 2009, 183, 5799-5806.
142. Khan, M.A.; Gallo, R.M.; Brutkiewicz, R.R. Anthrax Lethal Toxin Impairs CD1d-Mediated Antigen Presentation by Targeting the ERK1/2 MAPK Pathway. Infect. Immun.2010, doi:10.1128/IAI.01307-09.
143. Yang, J.; Woo, S.S.; Ryu, Y.H.; Yun, C.H.; Cho, M.H.; Rhie, G.E.; Kim, B.S.; Oh, H.B.; Han, S.H. Bacillus anthracis lethal toxin attenuates lipoteichoic acid-induced maturation and activation of dendritic cells through a unique mechanism. Mol. Immunol. 2009, 46, 3261-3268.
144. Agrawal, A.; Lingappa, J.; Leppla, S.H.; Agrawal, S.; Jabbar, A.; Quinn, C.; Pulendran, B. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 2003, 424, 329-334.
145. Maldonado-Arocho, F.J.; Bradley, K.A. Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta. Infect. Immun. 2009, 77, 2036-2042.
146. Maldonado-Arocho, F.J.; Fulcher, J.A.; Lee, B.; Bradley, K.A. Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells. Mol. Microbiol. 2006, 61, 324-337.
147. Alileche, A.; Serfass, E.R.; Muehlbauer, S.M.; Porcelli, S.A.; Brojatsch, J. Anthrax lethal toxin- mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog. 2005, 1, e19.
148. Comer, J.E.; Chopra, A.K.; Peterson, J.W.; Konig, R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect. Immun. 2005, 73, 8275-8281.
149. Fang, H.; Cordoba-Rodriguez, R.; Lankford, C.S.; Frucht, D.M. Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells. J. Immunol. 2005, 174, 4966-4971.
150. Paccani, S.R.; Tonello, F.; Ghittoni, R.; Natale, M.; Muraro, L.; D'Elios, M.M.; Tang, W.J.; Montecucco, C.; Baldari, C.T. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 2005, 201, 325-331.
151. Fang, H.; Xu, L.; Chen, T.Y.; Cyr, J.M.; Frucht, D.M. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J. Immunol. 2006, 176, 6155-6161.
152. Lee, D.Y.; Chun, J.H.; Ha, H.J.; Park, J.; Kim, B.S.; Oh, H.B.; Rhie, G.E. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits. FEMS Immunol. Med. Microbiol. 2009, 57, 165-172.
153. Stirpe, F.; Battelli, M.G. Ribosome-inactivating proteins: progress and problems. Cell. Mol. Life Sci. 2006, 63, 1850-1866.
154. Lubelli, C.; Chatgilialoglu, A.; Bolognesi, A.; Strocchi, P.; Colombatti, M.; Stirpe, F. Detection of ricin and other ribosome-inactivating proteins by an immuno-polymerase chain reaction assay. Anal. Biochem. 2006, 355, 102-109.
155. O'Hare, M.; Roberts, L.M.; Lord, J.M. Biological activity of recombinant Ricinus communis agglutinin A chain produced in Escherichia coli. FEBS Lett. 1992, 299, 209-212.
156. Furstenberg, C. Computer genereated model of Ricin toxin. Lund University, Lund, Sweden, 2008.
157. Endo, Y.; Tsurugi, K. The RNA N-glycosidase activity of ricin A-chain. The characteristics of the enzymatic activity of ricin A-chain with ribosomes and with rRNA. J. Biol. Chem. 1988, 263, 8735-8739.
158. Chiou, J.C.; Li, X.P.; Remacha, M.; Ballesta, J.P.; Tumer, N.E. The ribosomal stalk is required for ribosome binding, depurination of the rRNA and cytotoxicity of ricin A chain in Saccharomyces cerevisiae. Mol. Microbiol. 2008, 70, 1441-1452.
159. Ogasawara, T.; Sawasaki, T.; Morishita, R.; Ozawa, A.; Madin, K.; Endo, Y. A new class of enzyme acting on damaged ribosomes: ribosomal RNA apurinic site specific lyase found in wheat germ. EMBO J. 1999, 18, 6522-6531.
160. Eiklid, K.; Olsnes, S.; Pihl, A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp. Cell Res. 1980, 126, 321-326.
161. Marsden, C.J.; Fulop, V.; Day, P.J.; Lord, J.M. The effect of mutations surrounding and within the active site on the catalytic activity of ricin A chain. Eur. J. Biochem. 2004, 271, 153-162.
162. Schlossman, D.; Withers, D.; Welsh, P.; Alexander, A.; Robertus, J.; Frankel, A. Role of glutamic acid 177 of the ricin toxin A chain in enzymatic inactivation of ribosomes. Mol. Cell Biol. 1989, 9, 5012-5021.
163. Spilsberg, B.; Van Meer, G.; Sandvig, K. Role of lipids in the retrograde pathway of ricin intoxication. Traffic 2003, 4, 544-552.
164. Endo, Y.; Mitsui, K.; Motizuki, M.; Tsurugi, K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem. 1987, 262, 5908-5912.
165. Endo, Y.; Tsurugi, K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 1987, 262, 8128-8130.
166. Rothberg, K.G.; Ying, Y.S.; Kamen, B.A.; Anderson, R.G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J. Cell. Biol. 1990, 111, 2931-2938.
167. Rodal, S.K.; Skretting, G.; Garred, O.; Vilhardt, F.; van Deurs, B.; Sandvig, K. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated Endocytic vesicles. Mol. Biol. Cell. 1999, 10, 961-974.
168. Lombardi, D.; Soldati, T.; Riederer, M.A.; Goda, Y.; Zerial, M.; Pfeffer, S.R. Rab9 functions in transport between late Endosomes and the trans Golgi network. EMBO J. 1993, 12, 677-682.
169. Iversen, T.G.; Skretting, G.; Llorente, A.; Nicoziani, P.; van Deurs, B.; Sandvig, K. Endosome to Golgi transport of ricin is independent of clathrin and of the Rab9- and Rab11-GTPases. Mol. Biol. Cell. 2001, 12, 2099-2107.
170. Grimmer, S.; Iversen, T.G.; van Deurs, B.; Sandvig, K. Endosome to Golgi transport of ricin is regulated by cholesterol. Mol. Biol. Cell. 2000, 11, 4205-4216.
171. Moisenovich, M.; Tonevitsky, A.; Maljuchenko, N.; Kozlovskaya, N.; Agapov, I.; Volknandt, W.; Bereiter-Hahn, J. Endosomal ricin transport: involvement of Rab4- and Rab5-positive compartments. Histochem. Cell. Biol. 2004, 121, 429-439.
172. Day, P.J.; Owens, S.R.; Wesche, J.; Olsnes, S.; Roberts, L.M.; Lord, J.M. An interaction between ricin and calreticulin that may have implications for toxin trafficking. J. Biol. Chem. 2001, 276, 7202-7208.
173. Richardson, P.T.; Westby, M.; Roberts, L.M.; Gould, J.H.; Colman, A.; Lord, J.M. Recombinant proricin binds galactose but does not depurinate 28 S ribosomal RNA. FEBS Lett. 1989, 255, 15-20.
174. Sandvig, K.; van Deurs, B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol. Rev. 1996, 76, 949-966.
175. Spooner, R.A.; Watson, P.D.; Marsden, C.J.; Smith, D.C.; Moore, K.A.; Cook, J.P.; Lord, J.M.; Roberts, L.M. Protein disulphide-isomerase reduces ricin to its A and B chains in the Endoplasmic reticulum. Biochem. J. 2004, 383, 285-293.
176. Bellisola, G.; Fracasso, G.; Ippoliti, R.; Menestrina, G.; Rosen, A.; Solda, S.; Udali, S.; Tomazzolli, R.; Tridente, G.; Colombatti, M. Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. Biochem. Pharmacol. 2004, 67, 1721-1731.
177. Day, P.J.; Pinheiro, T.J.; Roberts, L.M.; Lord, J.M. Binding of ricin A-chain to negatively charged phospholipid vesicles leads to protein structural changes and destabilizes the lipid bilayer. Biochemistry 2002, 41, 2836-2843.
178. Griffiths, G.D.; Lindsay, C.D.; Allenby, A.C.; Bailey, S.C.; Scawin, J.W.; Rice, P.; Upshall, D.G. Protection against inhalation toxicity of ricin and abrin by immunisation. Hum. Exp. Toxicol. 1995, 14, 155-164.
179. Hewetson, J.F.; Rivera, V.R.; Creasia, D.A.; Lemley, P.V.; Rippy, M.K.; Poli, M.A. Protection of mice from inhaled ricin by vaccination with ricin or by passive treatment with heterologous antibody. Vaccine 1993, 11, 743-746.
180. Godal, A.; Fodstad, O.; Pihl, A. Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice. Int. J. Cancer 1983, 32, 515-521.
181. Foxwell, B.M.; Donovan, T.A.; Thorpe, P.E.; Wilson, G. The removal of carbohydrates from ricin with Endoglycosidases H, F and D and alpha-mannosidase. Biochim. Biophys. Acta 1985, 840, 193-203.
182. Foxwell, B.M.; Detre, S.I.; Donovan, T.A.; Thorpe, P.E. The use of anti-ricin antibodies to protect mice intoxicated with ricin. Toxicology 1985, 34, 79-88.
183. Ready, M.P.; Kim, Y.; Robertus, J.D. Site-directed mutagenesis of ricin A-chain and implications for the mechanism of action. Proteins 1991, 10, 270-278.
184. Lemley, P.V.; Amanatides, P.; Wright, D.C. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 1994, 13, 417-421.
185. Colombatti, M.; Johnson, V.G.; Skopicki, H.A.; Fendley, B.; Lewis, M.S.; Youle, R.J. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. J. Immunol. 1987, 138, 3339-3344.
186. Lebeda, F.J.; Olson, M.A. Prediction of a conserved, neutralizing epitope in ribosome-inactivating proteins. Int. J. Biol. Macromol. 1999, 24, 19-26.
187. Maddaloni, M.; Cooke, C.; Wilkinson, R.; Stout, A.V.; Eng, L.; Pincus, S.H. Immunological characteristics associated with the protective efficacy of antibodies to ricin. J. Immunol. 2004, 172, 6221-6228.
188. Mantis, N.J. Vaccines against the category B toxins: Staphylococcal enterotoxin B, epsilon toxin and ricin. Adv. Drug Deliv. Rev. 2005, 57, 1424-1439.
189. Thorpe, P.E.; Detre, S.I.; Foxwell, B.M.; Brown, A.N.; Skilleter, D.N.; Wilson, G.; Forrester, J.A.; Stirpe, F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur. J. Biochem. 1985, 147, 197-206.
190. Griffiths, G.D.; Bailey, S.C.; Hambrook, J.L.; Keyte, M.; Jayasekera, P.; Miles, J.; Williamson, E. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 1997, 15, 1933-1939.
191. Yan, C.; Rill, W.L.; Malli, R.; Hewetson, J.; Tammariello, R.; Kende, M. Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers. Vaccine 1995, 13, 645-651.
192. Kende, M.; Yan, C.; Hewetson, J.; Frick, M.A.; Rill, W.L.; Tammariello, R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 2002, 20, 1681-1691.
193. Mathew, M.; Verma, R.S. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009, 100, 1359-1365.
194. Piascik, P. FDA approves fusion protein for treatment of lymphoma. J. Am. Pharm. Assoc. (Wash.) 1999, 39, 571-572.
195. Carter, J.E., III; Odumosu, O.; Langridge, W.H. Expression of a ricin toxin B subunit: insulin fusion protein in edible plant tissues. Mol. Biotechnol. 2009, 44, 90-100.
196. Kobayashi, M.; Abiru, N.; Arakawa, T.; Fukushima, K.; Zhou, H.; Kawasaki, E.; Yamasaki, H.; Liu, E.; Miao, D.; Wong, F.S.; Eisenbarth, G.S.; Eguchi, K. Altered B:9-23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes. J. Immunol. 2007, 179, 2082-2088.
197. Arakawa, T.; Yu, J.; Langridge, W.H. Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Adv. Exp. Med. Biol. 1999, 464, 161-178.
198. Denes, B.; Fodor. I.; Langridge, W. Autoantigen plus interleukin-10 suppress diabetes autoimmunity. Diabetes Technol. Ther. 2010, submitted for publication.
199. Fensterle, J.; Bergmann, B.; Yone, C.L.; Hotz, C.; Meyer, S.R.; Spreng, S.; Goebel, W.; Rapp, U.R.; Gentschev, I. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther. 2008, 15, 85-93.
200. Peppoloni, S.; Ruggiero, P.; Contorni, M.; Morandi, M.; Pizza, M.; Rappuoli, R.; Podda, A.; Del Giudice, G. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2003, 2, 285-293.
201. Lewis, D.J.; Huo, Z.; Barnett, S.; Kromann, I.; Giemza, R.; Galiza, E.; Woodrow, M.; Thierry-Carstensen, B.; Andersen, P.; Novicki, D.; Del Giudice, G.; Rappuoli, R. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4, e6999